Clinical Trial Update: A Drug Drug Interaction Study to Evaluate the Effect of VCT220 on the Pharmacokinetics of Repaglinide, Rosuvastatin, and Digoxin in Healthy, Overweight, and Obese Subjects [Phase 1]

View source ↗

Summary

Phase 1 trial assessing how VCT220 affects the pharmacokinetics of repaglinide, rosuvastatin, and digoxin in healthy overweight and obese subjects.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Obesity

Drugs mentioned

• DIGOXIN (Digoxin)
• Repaglinide (Repaglinide)
• Rosuvastatin (rosuvastatin)
• VCT220

Snippet

Sponsor: Vincentage Pharma Co., Ltd | Conditions: Obesity &Amp; Overweight | Phase 1 | Status: COMPLETED